We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Prostate Cancer Biomarkers Identified in Seminal Fluid

By LabMedica International staff writers
Posted on 18 Jun 2014
Print article
Image: Histopathology micrograph of prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Nephron).
Image: Histopathology micrograph of prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Nephron).
Improved diagnosis and management of one of the most common cancers in men, prostate cancer, could result from discovery that seminal fluid contains biomarkers for the disease.

The presence of certain small ribonucleic acids (miRNA) in seminal fluid indicates not only whether a man has prostate cancer, but also the severity of the cancer, which would be an improvement on the commonly used prostate specific antigen (PSA) test which is not by itself ideal to test for the cancer.

Scientists at the University of Adelaide (Australia) collected seminal fluid (SF) samples attending a Urology Outpatient clinic. Two RNA pools, representing groups of men with low/intermediate risk cancer or men without cancer, were compared. Men in both groups had elevated serum PSA levels to increase the likelihood of identifying miRNA biomarkers that would provide additional diagnostic information.

RNA was extracted using Trizol reagent (Life Technologies; Carlsbad, CA, USA) and cleaned up with RNeasy Mini kits (Qiagen; Hilden, Germany). Deep sequencing using the TruSeq Small RNA work flow (Illumina; San Diego, CA, USA) was used to analyze the small RNA population in the non-sperm cellular fraction of SF, which includes prostatic epithelial, urothelial, and inflammatory cells.

Hierarchical clustering based on these miRNAs yielded two major branches one of which was characterized by higher levels of the SF miRNAs and was largely composed of men with biopsy proven disease and the other characterized by lower SF miRNA levels and men with negative biopsies. These findings support the concept that individual SF miRNAs or an SF miRNA signature could be useful diagnostic tools.

Luke A. Selth, PhD, the lead author of the study said, “The presence of these microRNAs enabled us to more accurately discriminate between patients who had cancer and those who didn't, compared with a standard PSA test. We also found that the one specific microRNA, miR-200b, could distinguish between men with low grade and higher grade tumors. This is important because, as a potential prognostic tool, it will help to indicate the urgency and type of treatment required.” The study was published on May 23, 2014, in the journal Endocrine Related Cancer.

Related Links:

University of Adelaide
Life Technologies
Qiagen 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.